China

BMI View: Potential approval of the first traditional Chinese medicine (TCM) by the US Food and Drug Administration (FDA) would be a huge landmark for the beleaguered TCM sector and... 2011-11-25

BMI View: China is the world's most attractive emerging pharmaceutical market. The key driver of growth is the government's commitment to providing affordable universal healthcare.... 2011-11-24

BMI View: Despite the upward revision to our Indian healthcare expenditure forecast, we continue to expect Chinese outperformance in the healthcare sector over the medium-to-long term,... 2011-11-14

BMI Core View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated and BMI 's Pharmaceutical Expenditure... 2011-11-10

BMI View: Multinational pharmaceutical companies will increasingly look to China's second-tier cities as locations for their manufacturing plants, sales offices and, to a lesser extent,... 2011-10-24

BMI View: Sinopharm has very strong research and development (R&D) capabilities given that it has six subsidiaries focusing on the introduction of innovative biopharmaceutical products.... 2011-10-20

BMI Core View: Offshoring manufacturing to low cost bases will become increasingly prevalent. Multinational drugmakers are looking to cut costs ahead of the patent cliff and production... 2011-10-11